Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HU-045 vs Xeomin in Moderate or Severe Glabellar Lines
NCT07870694Phase 3Recruiting
- Sponsor
- Huons Biopharma
- Start
- Sep 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HU-045 in glabellar lines (2 arms), sponsored by Huons Biopharma. Primary endpoint: Percentage of Participants Whose Glabellar Lines at Maximal Frown Are Improved as Assessed by the Investigator at 4 weeks. Started Sep 2026; status: recruiting.
02
Drugs
HU-045
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT07870694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07870694.